|
|
|
Volumn 12, Issue 5, 2009, Pages 291-293
|
|
American college of cardiology - 58th annual scientific session
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2,4 THIAZOLIDINEDIONE DERIVATIVE;
ALEGLITAZAR;
ANACETRAPIB;
APOLIPOPROTEIN A1;
APOLIPOPROTEIN A1 MIMETIC AGENT;
APP 018;
ATORVASTATIN;
ATORVASTATIN PLUS TORCETRAPIB;
CARDIOVASCULAR AGENT;
CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR;
D 4F;
DALCETRAPIB;
FENOFIBRATE;
FIBRIC ACID DERIVATIVE;
HIGH DENSITY LIPOPROTEIN;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LAROPIPRANT;
LOW DENSITY LIPOPROTEIN;
MYELOPEROXIDASE;
NICOTINIC ACID;
NICOTINIC ACID PLUS LAROPIPRANT;
NICOTINIC ACID PLUS SIMVASTATIN;
OMEGA 3 FATTY ACID;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST;
PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;
RIMONABANT;
ROSUVASTATIN;
RVX 208;
SIMVASTATIN;
TORCETRAPIB;
TREDAPTIVE;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ATHEROSCLEROSIS;
ATHEROSCLEROTIC PLAQUE;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CHOLESTEROL BLOOD LEVEL;
CHOLESTEROL TRANSPORT;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED DRUG RELEASE;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG TARGETING;
EXERCISE;
FLUSHING;
FUNCTIONAL PROTEOMICS;
HUMAN;
LIPOPROTEIN BLOOD LEVEL;
LIPOPROTEIN METABOLISM;
NONHUMAN;
PROTEIN FUNCTION;
PRURITUS;
RISK REDUCTION;
SIDE EFFECT;
UNSPECIFIED SIDE EFFECT;
APOLIPOPROTEIN A-I;
CARDIOVASCULAR AGENTS;
CARDIOVASCULAR DISEASES;
DRUG DESIGN;
HUMANS;
LIPOPROTEINS, HDL;
|
|
EID: 67649361967
PISSN: 13697056
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (1)
|
|
References (0)
|
